HK1197176A1 - Topical ophthalmological pharmaceutical composition containing regorafenib - Google Patents

Topical ophthalmological pharmaceutical composition containing regorafenib

Info

Publication number
HK1197176A1
HK1197176A1 HK14110517A HK14110517A HK1197176A1 HK 1197176 A1 HK1197176 A1 HK 1197176A1 HK 14110517 A HK14110517 A HK 14110517A HK 14110517 A HK14110517 A HK 14110517A HK 1197176 A1 HK1197176 A1 HK 1197176A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
topical ophthalmological
containing regorafenib
Prior art date
Application number
HK14110517A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Bttger
Degenfeld Georges Von
Julia Freundlieb
Claudia Hirth-Dietrich
Joerg Keldenich
Jrgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Riedl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1197176(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1197176A1 publication Critical patent/HK1197176A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK14110517A 2011-06-28 2014-10-22 Topical ophthalmological pharmaceutical composition containing regorafenib HK1197176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14
PCT/EP2012/062365 WO2013000917A1 (fr) 2011-06-28 2012-06-26 Composition pharmaceutique topique ophtalmologique contenant du régorafénib

Publications (1)

Publication Number Publication Date
HK1197176A1 true HK1197176A1 (en) 2015-01-09

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110517A HK1197176A1 (en) 2011-06-28 2014-10-22 Topical ophthalmological pharmaceutical composition containing regorafenib

Country Status (25)

Country Link
US (1) US20140296301A1 (fr)
EP (1) EP2726059A1 (fr)
JP (1) JP5998213B2 (fr)
KR (1) KR20140048218A (fr)
CN (1) CN103889399A (fr)
AP (1) AP2013007335A0 (fr)
AR (1) AR086800A1 (fr)
AU (1) AU2012277905A1 (fr)
BR (1) BR112013033831A2 (fr)
CA (1) CA2840329A1 (fr)
CL (1) CL2013003700A1 (fr)
CO (1) CO6920289A2 (fr)
CR (1) CR20130693A (fr)
CU (1) CU24163B1 (fr)
DO (1) DOP2013000314A (fr)
EA (1) EA201400064A1 (fr)
EC (1) ECSP13013106A (fr)
GT (1) GT201300322A (fr)
HK (1) HK1197176A1 (fr)
MX (1) MX2013015287A (fr)
PE (1) PE20141031A1 (fr)
TN (1) TN2013000533A1 (fr)
UY (1) UY34166A (fr)
WO (1) WO2013000917A1 (fr)
ZA (1) ZA201400646B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (fr) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
KR20220080222A (ko) 2016-06-02 2022-06-14 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
ATE485821T1 (de) * 2002-05-28 2010-11-15 Nycomed Gmbh Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
PT1885336E (pt) 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
CA2611720A1 (fr) 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
PL1968594T3 (pl) 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
JP2009519267A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア
WO2007076358A1 (fr) 2005-12-23 2007-07-05 Alcon, Inc. Preparation pharmaceutique pour l'administration, dans l'oeil, de composes inhibiteurs des récepteurs tyrosine kinases (rtki)
WO2008027341A2 (fr) 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2008308489A (ja) * 2007-05-11 2008-12-25 Santen Pharmaceut Co Ltd ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
CA2760687A1 (fr) 2009-05-01 2010-11-04 Ophthotech Corporation Procedes de traitement ou de prevention de maladies ophtalmologiques
CA2768237A1 (fr) 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Methode de traitement

Also Published As

Publication number Publication date
CO6920289A2 (es) 2014-04-10
TN2013000533A1 (en) 2015-03-30
AP2013007335A0 (en) 2013-12-31
CN103889399A (zh) 2014-06-25
NZ619229A (en) 2016-04-29
PE20141031A1 (es) 2014-08-21
ECSP13013106A (es) 2014-01-31
JP5998213B2 (ja) 2016-09-28
US20140296301A1 (en) 2014-10-02
CA2840329A1 (fr) 2013-01-03
DOP2013000314A (es) 2014-04-15
AR086800A1 (es) 2014-01-22
AU2012277905A1 (en) 2014-01-16
EA201400064A1 (ru) 2014-05-30
CR20130693A (es) 2016-05-02
CL2013003700A1 (es) 2014-07-18
CU20130168A7 (es) 2014-04-24
UY34166A (es) 2013-01-31
MX2013015287A (es) 2014-03-31
JP2014518233A (ja) 2014-07-28
EP2726059A1 (fr) 2014-05-07
ZA201400646B (en) 2015-11-25
AU2012277905A8 (en) 2014-01-30
KR20140048218A (ko) 2014-04-23
CU24163B1 (es) 2016-03-31
WO2013000917A1 (fr) 2013-01-03
BR112013033831A2 (pt) 2017-02-14
GT201300322A (es) 2014-11-13

Similar Documents

Publication Publication Date Title
HK1214170A1 (zh) 含有瑞戈非尼的包衣的藥物組合物
AP3864A (en) Pharmaceutical composition
HK1204564A1 (en) Topical ophthalmological pharmaceutical composition containing axitinib
HK1197176A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
GB201118232D0 (en) Pharmaceutical composition
HK1204563A1 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
EP2702989A4 (fr) Composition pharmaceutique stable
HK1189158A1 (en) Pharmaceutical composition
EP2769718A4 (fr) Composition médicinale
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
EP2685993A4 (fr) Compositions pharmaceutiques et utilisation topique de celles-ci
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1204289A1 (en) Topical ophthalmological pharmaceutical composition containing cediranib
EP2727593A4 (fr) Composition pharmaceutique contenant du nicorandil
EP2711010A4 (fr) Composition pharmaceutique
HUP1100444A2 (en) Pharmaceutical composition
EP2883546A4 (fr) Nouvelle composition pharmaceutique à libération différentielle contenant trois principes actifs
EP2851074A4 (fr) Composition pharmaceutique analgésique
EP2727594A4 (fr) Nouvelle composition pharmaceutique
HUP1100445A2 (en) Pharmaceutical composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
AU2011905393A0 (en) Pharmaceutical Composition